We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.

New Oncotype DX GPS Study


New Study Adds Additional Endpoints of Mortality and Metastases to Oncotype DX GPS to Help Newly-Diagnosed Prostate Cancer Patients Make Even More Confident Treatment Decisions

Patients with newly diagnosed, localized prostate cancer have been able to use the Oncotype DX® Genomic Prostate Score (GPS)™ test to help them confidently decide between active surveillance and aggressive treatment. Now with additional information through GPS, men and their families can have an even more informed treatment discussion with their physicians.

Recently published in European Urology, a large multi-center validation study with Kaiser Permanente confirmed that the GPS result is a strong independent predictor of prostate cancer-specific death (mortality) and disease progression (metastases) at 10 years in men with localized prostate cancer across all National Comprehensive Cancer Network (NCCN)® clinical risk groups.

Researchers in the study evaluated biopsy tissue from 259 patients across all risk categories, age and race who were treated with surgery, or radical prostatectomy, then followed for approximately 10 years.

Adverse Pathology
Biochemical Recurrence


An additional key finding was that patients with very low-, low- or intermediate-risk prostate cancer and a GPS result of less than 20 did not develop metastatic disease or die from prostate cancer following radical prostatectomy.

With these results, the Oncotype DX GPS test becomes the only prostate cancer genomic test validated for all major near- and long-term endpoints, including adverse pathology, biochemical recurrence, metastasis and prostate cancer-specific death.


Learn more

Oncotype DX My Colon Cancer Coach